. Author manuscript; available in PMC: 2016 Jun 1.

Published in final edited form as: Br J Psychiatry. 2015 Mar 5;206(6):484–491. doi: 10.1192/bjp.bp.114.151837

Table 3.

Reasons reported for initial discontinuation of clozapine treatment and success of clozapine retrials in adults with 22q11.2 deletion syndrome (22q11.2DS) schizophrenia compared with idiopathic schizophrenia

Reason	n
22q11.2DS schizophrenia group	12
Serious adverse effects	6
Red zone neutropenia	3
Seizures	2^a
Myocarditis	1
Insufficient clinical improvement^b	2^a
Non-adherence/weight gain	1
Tachycardia/hypertension	1^a
Tachycardia/venipuncture difficulties	1^a
Venipuncture difficulties	1^a

Idiopathic schizophrenia group	9
Non-adherence	2^a
Unknown	2
Sedation	1
Sedation/unsteadiness	1^a
Heartburn	1
Other gastrointestinal complaints	1
Venipuncture difficulties/‘feeling funny’	1

Denotes successful retrial (n = 1) each: showed clinical improvement with retrial of clozapine and has had no further discontinuations.

One patient responded well to clozapine before the development of Parkinson’s disease and subsequent treatment changes (for example clozapine dose reduction to 100 mg with patient non-adherence and trials with adjunctive antipsychotics and electroconvulsive treatment). The other patient was treated with clozapine before discontinuing at approximately 6 months (maintenance dose 275 mg) and had a successful clozapine retrial (maintenance dose 300 mg).